Follow The Filings

PTGX position history

The shares of Protagonist Therapeutics (PTGX) that FARALLON CAPITAL MANAGEMENT, L.L.C. reported in each quarter’s 13F.

Equity, COM

Shares held by quarter

New Add Reduce Exit

  1. 2021 Q3: 2,392,000 shares, $42M, 0.21% of portfolio
  2. 2021 Q4: 1,917,134 shares, $66M, 0.35% of portfolio, Reduce −19.9%
  3. 2022 Q1: 1,134,457 shares, $27M, 0.14% of portfolio, Reduce −40.8%
  4. 2022 Q2: 3,700,608 shares, $29M, 0.18% of portfolio, Add +226.2%
  5. 2022 Q3: 3,651,887 shares, $31M, 0.18% of portfolio, Reduce −1.3%
  6. 2022 Q4: 3,651,887 shares, $40M, 0.26% of portfolio
  7. 2023 Q1: 2,615,014 shares, $60M, 0.34% of portfolio, Reduce −28.4%
  8. 2023 Q2: 4,511,430 shares, $125M, 0.70% of portfolio, Add +72.5%
  9. 2023 Q3: 5,446,430 shares, $91M, 0.46% of portfolio, Add +20.7%
  10. 2023 Q4: 5,734,430 shares, $131M, 0.65% of portfolio, Add +5.3%
  11. 2024 Q1: 11,477,946 shares, $332M, 1.5% of portfolio, Add +100.2%
  12. 2024 Q2: 5,840,773 shares, $202M, 0.96% of portfolio, Reduce −49.1%
  13. 2024 Q3: 5,861,006 shares, $264M, 1.3% of portfolio, Add +0.3%
  14. 2024 Q4: 5,930,006 shares, $229M, 1.2% of portfolio, Add +1.2%
  15. 2025 Q1: 6,107,006 shares, $295M, 1.6% of portfolio, Add +3.0%
  16. 2025 Q2: 6,172,006 shares, $341M, 1.5% of portfolio, Add +1.1%
  17. 2025 Q3: 12,392,012 shares, $823M, 3.4% of portfolio, Add +100.8%
  18. 2025 Q4: 6,144,006 shares, $537M, 2.5% of portfolio, Reduce −50.4%
  19. 2026 Q1: 6,348,906 shares, $669M, 3.8% of portfolio, Add +3.3%
  20. 2026 Q2: 6,348,906 shares, $778M, 3.6% of portfolio
  21. 2026 Q3: 6,437,906 shares, $907M, 3.9% of portfolio, Add +1.4%
Holdings date Value % of holdings Shares Filing date All 13F holders